<DOC>
	<DOCNO>NCT01255657</DOCNO>
	<brief_summary>This open-label study design determine recommend Phase 2 dose ( RPTD ) evaluate safety pharmacokinetics ABT-806 subject advance solid tumor .</brief_summary>
	<brief_title>A Study ABT-806 Subjects With Advanced Solid Tumor Types</brief_title>
	<detailed_description />
	<criteria>Subject solid tumor type know either overexpress wildtype EGFR express variant III mutant EGFR ( e.g. , head neck squamous cell carcinoma , non small cell lung cancer ( NSCLC ) , colorectal carcinoma ) tumor know EGFR positive . Subject must disease amenable surgical resection approve therapeutic option curative intent . Subject Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . Subject must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 . Inclusion criterion Expand Safety Cohort B subject histologically confirm supratentorial glioblastoma multiforme ( GBM ) . Subject uncontrolled metastasis central nervous system . Subjects brain metastasis eligible provide show clinical radiographic stable disease least 1 month definitive therapy . Subjects glioblastoma multiforme ( GBM ) exclude dose escalation portion study , may enrol expand safety cohort . Subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , biologic , investigational therapy within period 21 day prior first dose ABT806 . Subject adjustment ongoing steroid medication 14 day prior first dose ABT806 . Subject receive prior EGFRdirected monoclonal antibody within period 4 week prior first dose ABT806 . Subject unresolved clinically significant toxicity prior anticancer therapy , define Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 high .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>